NLGN1 and autism: It also points to specific RTKs as potential pharmacological targets to modulate the synaptic balance in the brain, for example in the context of neurodevelopmental disorders such as autism (Bourgeron, 2015), which in some individuals has been associated to genetic mutations in NLGN1 (Nakanishi et al., 2017).